Frédéric Amant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5006330/publications.pdf

Version: 2024-02-01

510 papers

28,703 citations

76 h-index 148 g-index

526 all docs

526 docs citations

times ranked

526

27966 citing authors

#	Article	lF	CITATIONS
1	Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine, 2010, 363, 943-953.	27.0	2,066
2	Endometrial cancer. Lancet, The, 2005, 366, 491-505.	13.7	1,368
3	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	9.4	1,341
4	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
5	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature, 2016, 537, 63-68.	27.8	521
6	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International Journal of Gynecological Cancer, 2016, 26, 2-30.	2.5	515
7	Melanoma addiction to the long non-coding RNA SAMMSON. Nature, 2016, 531, 518-522.	27.8	488
8	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT. Journal of Clinical Oncology, 2008, 26, 1664-1670.	1.6	460
9	Cancer During Pregnancy: An Analysis of 215 Patients Emphasizing the Obstetrical and the Neonatal Outcomes. Journal of Clinical Oncology, 2010, 28, 683-689.	1.6	377
10	Clinical management of uterine sarcomas. Lancet Oncology, The, 2009, 10, 1188-1198.	10.7	374
11	Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation With Impaired Cognitive Functioning. Journal of Clinical Oncology, 2012, 30, 274-281.	1.6	334
12	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
13	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2018, 143, 37-50.	2.3	290
14	Pathology and physiopathology of adenomyosis. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 511-521.	2.8	283
15	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. New England Journal of Medicine, 2015, 373, 1824-1834.	27.0	283
16	HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer, 2011, 104, 863-870.	6.4	270
17	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2012, 36, 641-653.	3.7	265
18	Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 2532-2539.	1.6	261

#	Article	IF	CITATIONS
19	Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2004, 18, 349-371.	2.8	257
20	Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. International Journal of Gynecological Cancer, 2003, 13, 522-527.	2.5	241
21	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	7.1	239
22	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	2.8	238
23	Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncology, The, 2012, 13, 256-264.	10.7	237
24	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
25	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncology, The, 2018, 19, 337-346.	10.7	235
26	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	6.3	229
27	Chemotherapyâ€induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human Brain Mapping, 2011, 32, 480-493.	3.6	228
28	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. Development (Cambridge), 2017, 144, 1775-1786.	2.5	228
29	Treatment of breast cancer during pregnancy: an observational study. Lancet Oncology, The, 2012, 13, 887-896.	10.7	224
30	Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound in Obstetrics and Gynecology, 1999, 13, 11-16.	1.7	216
31	Breast cancer in pregnancy. Lancet, The, 2012, 379, 570-579.	13.7	216
32	Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. International Journal of Gynecological Cancer, 2014, 24, 394-403.	2.5	198
33	Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. European Radiology, 2014, 24, 889-901.	4.5	189
34	Ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 159-179.	4.4	186
35	L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. Journal of the National Cancer Institute, 2013, 105, 1142-1150.	6.3	185
36	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. JAMA Oncology, 2015, 1, 814.	7.1	180

#	Article	IF	Citations
37	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
38	Management of Borderline Ovarian Neoplasms. Journal of Clinical Oncology, 2007, 25, 2928-2937.	1.6	174
39	Breast Cancer Diagnosed During Pregnancy. JAMA Oncology, 2015, 1, 1145.	7.1	169
40	ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2015, 117, 559-581.	0.6	167
41	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2012, 119, S110-7.	2.3	149
42	Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecologic Oncology, 2005, 98, 274-280.	1.4	142
43	Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of Clinical Pathology, 2005, 58, 611-616.	2.0	141
44	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics, 2011, 43, 451-454.	21.4	141
45	Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology, The, 2012, 13, 154-162.	10.7	141
46	Cancer of the corpus uteri: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 45-60.	2.3	139
47	Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. Journal of Clinical Investigation, 2015, 126, 68-84.	8.2	138
48	Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. British Journal of Cancer, 2007, 97, 1194-1199.	6.4	136
49	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	2.2	135
50	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer, 2013, 49, 3431-3441.	2.8	123
51	Identification of a novel, recurrent <i>MBTD1â€CXorf67</i> fusion in lowâ€grade endometrial stromal sarcoma. International Journal of Cancer, 2014, 134, 1112-1122.	5.1	117
52	Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: A prospective controlled study. Breast, 2014, 23, 629-636.	2.2	116
53	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematology,the, 2015, 2, e55-e65.	4.6	115
54	Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. International Journal of Gynecological Cancer, 2005, 15, 776-779.	2.5	113

#	Article	IF	Citations
55	Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research, 2011, 17, 3368-3377.	7.0	113
56	Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Research and Treatment, 2007, 104, 87-91.	2.5	111
57	Lung cancer in pregnancy: Report of nine cases from an international collaborative study. Lung Cancer, 2013, 82, 499-505.	2.0	107
58	Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer, 2011, 47, S88-S92.	2.8	106
59	Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. Gynecologic Oncology, 2013, 128, 6-11.	1.4	105
60	Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer, 2012, 48, 1649-1656.	2.8	104
61	Gynecologic Cancers in Pregnancy. International Journal of Gynecological Cancer, 2009, 19, S1-S12.	2.5	103
62	Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine, 2012, 10, 86.	5.5	103
63	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 545-557.	4.2	102
64	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 1338-1345.	2.8	101
65	Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecologic Oncology, 2003, 88, 266-269.	1.4	99
66	Cervical neoplasia during pregnancy: Diagnosis, management and prognosis. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2005, 19, 611-630.	2.8	94
67	Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. International Journal of Gynecological Cancer, 2006, 16, 905-908.	2.5	93
68	Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. European Journal of Cancer, 2017, 83, 88-98.	2.8	93
69	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.9	92
70	Does Estrogen Receptor–Negative/Progesterone Receptor–Positive Breast Carcinoma Exist?. Journal of Clinical Oncology, 2008, 26, 335-336.	1.6	91
71	Recurrent <i>PPP2R1A</i> Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. Cancer Research, 2016, 76, 5719-5731.	0.9	89
72	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	19.2	88

#	Article	IF	Citations
73	Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. American Journal of Obstetrics and Gynecology, 2007, 196, 248.e1-248.e8.	1.3	87
74	Gynaecologic cancer complicating pregnancy: An overview. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2010, 24, 61-79.	2.8	85
75	Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecologic Oncology, 2010, 119, 594-600.	1.4	82
76	Modeling Endometrial Cancer: Past, Present, and Future. International Journal of Molecular Sciences, 2018, 19, 2348.	4.1	82
77	Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?. British Journal of Cancer, 2009, 101, 244-249.	6.4	80
78	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. Clinical Cancer Research, 2017, 23, 2223-2231.	7.0	80
79	Timing of debulking surgery in advanced ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 11-19.	2.5	79
80	Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. International Journal of Gynecological Cancer, 2002, 12, 22-26.	2.5	78
81	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. Journal of Clinical Oncology, 2016, 34, 501-508.	1.6	78
82	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
83	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Research and Treatment, 2009, 113, 181-187.	2.5	76
84	The immune system in the normal endometrium and implications for endometrial cancer development. Journal of Reproductive Immunology, 2015, 109, 7-16.	1.9	76
85	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British Journal of Cancer, 2016, 115, 716-724.	6.4	76
86	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma. International Journal of Gynecological Cancer, 2014, 24, S67-S72.	2.5	75
87	Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. International Journal of Gynecological Cancer, 2010, 20, 1456-64.	2.5	7 5
88	Screening for uterine tumours. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 257-266.	2.8	72
89	Pregnancy and Cancer: the INCIP Project. Current Oncology Reports, 2020, 22, 17.	4.0	72
90	The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecologic Oncology, 2003, 90, 37-43.	1.4	71

#	Article	IF	Citations
91	Sexual, Psychological, and Relational Functioning in Women After Surgical Treatment for Vulvar Malignancy: A Literature Review. Journal of Sexual Medicine, 2012, 9, 361-371.	0.6	71
92	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	4.5	71
93	Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. ELife, 2014, 3, e02725.	6.0	71
94	Robotic retroperitoneal lower paraâ€aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 783-787.	2.8	70
95	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2015, 131, S96-104.	2.3	70
96	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	1.6	70
97	High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology, 2013, 128, 327-334.	1.4	68
98	Longitudinal Assessment of Chemotherapy-Induced Alterations in Brain Activation During Multitasking and Its Relation With Cognitive Complaints. Journal of Clinical Oncology, 2014, 32, 2031-2038.	1.6	66
99	Progesterone Inhibits Epithelial-to-Mesenchymal Transition in Endometrial Cancer. PLoS ONE, 2012, 7, e30840.	2.5	66
100	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	2.5	64
101	Management of cancer in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 741-753.	2.8	63
102	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	3.1	62
103	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
104	Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 1066-1070.	2.3	61
105	Clinically oriented threeâ€step strategy for assessment of adnexal pathology. Ultrasound in Obstetrics and Gynecology, 2012, 40, 582-591.	1.7	61
106	Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology, 2014, 25, 2059-2065.	1.2	60
107	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Modern Pathology, 2015, 28, 1001-1010.	5 . 5	60
108	Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer. Journal of Clinical Oncology, 2011, 29, 4076-4078.	1.6	59

#	Article	IF	Citations
109	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	5.1	59
110	Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecologic Oncology, 2004, 93, 680-685.	1.4	58
111	Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. European Journal of Cancer, 2013, 49, 1600-1608.	2.8	57
112	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncology, The, 2021, 22, 753-754.	10.7	57
113	Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2005, 26, 644-650.	1.7	56
114	Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Research and Treatment, 2005, 91, 81-87.	2.5	56
115	Pseudo-Meigs' Syndrome Caused by a Hydropic Degenerating Uterine Leiomyoma with Elevated CA 125. Gynecologic Oncology, 2001, 83, 153-157.	1.4	55
116	ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecologic Oncology, 2004, 95, 583-587.	1.4	54
117	PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. Gynecologic Oncology, 2013, 131, 694-700.	1.4	54
118	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer, 2014, 50, 1462-1471.	2.8	54
119	Nuclear inclusion bodies of mutant and wildâ€type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. Journal of Pathology, 2017, 242, 24-38.	4.5	54
120	The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecologic Oncology, 2010, 117, 358-365.	1.4	53
121	Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study. International Journal of Gynecological Cancer, 2014, 24, 54-60.	2.5	52
122	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecologic Oncology, 2015, 139, 118-126.	1.4	52
123	Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?. Brain Imaging and Behavior, 2018, 12, 64-77.	2.1	52
124	Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. Journal of Clinical Oncology, 2010, 28, 4129-4134.	1.6	51
125	Cancer in pregnancy: a survey of current clinical practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 167, 18-23.	1.1	51
126	Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecologic Oncology, 2012, 125, 103-108.	1.4	50

#	Article	IF	CITATIONS
127	Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecologic Oncology, 2013, 130, 192-199.	1.4	50
128	Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. Gynecologic Oncology, 2015, 138, 299-303.	1.4	50
129	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
130	Difficulties with diagnosis of malignancies in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 33, 19-32.	2.8	50
131	Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Annals of Oncology, 2012, 23, 1449-1454.	1.2	49
132	Substantial Variation in Transplacental Transfer of Chemotherapeutic Agents in a Mouse Model. Reproductive Sciences, 2011, 18, 57-63.	2.5	48
133	Locoregional treatment of breast cancer during pregnancy. Gynecological Surgery, 2014, 11, 279-284.	0.9	48
134	Effects of cancer treatment during pregnancy on fetal and child development. The Lancet Child and Adolescent Health, 2017, 1, 302-310.	5.6	48
135	FIGO 2018 stage IB2 (2–4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study. International Journal of Gynecological Cancer, 2019, 29, 969-975.	2.5	48
136	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 2020, 63, 417-431.	1.6	48
137	Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecologic Oncology, 2003, 91, 265-271.	1.4	47
138	Chemotherapy for recurrent cervical cancer. Gynecologic Oncology, 2007, 107, S113-S118.	1.4	47
139	Management of pregnancy in women with cancer. International Journal of Gynecological Cancer, 2021, 31, 314-322.	2.5	47
140	Response: The classification of a uterine sarcoma as †High-grade endometrial stromal sarcoma†Meshould be abandoned. Gynecologic Oncology, 2004, 95, 412-413.	1.4	46
141	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Annals of Oncology, 2012, 23, 2578-2584.	1.2	46
142	Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. European Radiology, 2018, 28, 1862-1874.	4.5	46
143	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Modern Pathology, 2018, 31, 816-828.	5. 5	46
144	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer, 2019, 19, 506.	2.6	46

#	Article	IF	CITATIONS
145	PTEN Mutations in Uterine Sarcomas. Gynecologic Oncology, 2002, 85, 165-169.	1.4	45
146	Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecologic Oncology, 2006, 103, 1137-1140.	1.4	45
147	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2019, 6, e551-e561.	4.6	45
148	Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. European Journal of Cancer, 2007, 43, 1630-1637.	2.8	44
149	Sexual Functioning in Women After Surgical Treatment for Endometrial Cancer: A Prospective Controlled Study. Journal of Sexual Medicine, 2015, 12, 198-209.	0.6	44
150	A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound in Obstetrics and Gynecology, 2007, 29, 674-679.	1.7	43
151	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer, 2018, 28, 514-523.	2.5	43
152	New models to predict depth of infiltration in endometrial carcinoma based on transvaginal sonography. Ultrasound in Obstetrics and Gynecology, 2006, 27, 664-671.	1.7	42
153	Pelvic Exenterations for Gynecological Malignancies. International Journal of Gynecological Cancer, 2012, 22, 889-896.	2.5	42
154	The functional neuroanatomy of multitasking: Combining dual tasking with a short term memory task. Neuropsychologia, 2013, 51, 2251-2260.	1.6	42
155	Strategies for fertility preservation in young early breast cancer patients. Breast, 2014, 23, 503-510.	2.2	42
156	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. EClinicalMedicine, 2021, 35, 100856.	7.1	42
157	Immunohistochemical expression of CD10 antigen in uterine adenosarcoma. International Journal of Gynecological Cancer, 2004, 14, 1118-1121.	2.5	41
158	Ovarian cancer in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 108-117.	2.8	41
159	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188446.	7.4	41
160	Treatment modalities in endometrial cancer. Current Opinion in Oncology, 2007, 19, 479-485.	2.4	40
161	Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2IIIB. International Journal of Gynecological Cancer, 2008, 18, 723-729.	2.5	40
162	Tamoxifen and pregnancy: an absolute contraindication?. Breast Cancer Research and Treatment, 2019, 175, 17-25.	2.5	40

#	Article	IF	CITATIONS
163	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. Cancers, 2021, 13, 5848.	3.7	40
164	Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Annals of Oncology, 2005, 16, 1755-1761.	1.2	39
165	Hyperreactio luteinalis in a spontaneously conceived singleton pregnancy. Ultrasound in Obstetrics and Gynecology, 2009, 33, 371-373.	1.7	39
166	Clinical Recommendation on Fertility Preservation in Borderline Ovarian Neoplasm: Ovarian Stimulation and Oocyte Retrieval after Conservative Surgery. Gynecologic and Obstetric Investigation, 2010, 70, 160-165.	1.6	39
167	Chemotherapy during pregnancy. Current Opinion in Oncology, 2012, 24, 580-586.	2.4	39
168	Classification of radical hysterectomy adopted by the Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer. International Journal of Gynecological Cancer, 2008, 18, 1136-1138.	2.5	38
169	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	1.4	38
170	The "Leuven―dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecologic Oncology, 2007, 106, 354-361.	1.4	37
171	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research, 2017, 23, 7232-7241.	7.0	37
172	Immunotherapy for cancer treatment during pregnancy. Lancet Oncology, The, 2021, 22, e550-e561.	10.7	37
173	Wilms' Tumor Gene 1 (WT1)loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Research, 2013, 33, 5495-500.	1.1	37
174	Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods. Ultrasound in Obstetrics and Gynecology, 2007, 29, 496-504.	1.7	36
175	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Human Pathology, 2014, 45, 522-532.	2.0	36
176	Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Research, 2013, 33, 3855-9.	1.1	36
177	Microsatellite instability in uterine sarcomas. International Journal of Gynecological Cancer, 2001, 11, 218-223.	2.5	35
178	In Utero Exposure to Chemotherapy: Effect on Cardiac and Neurologic Outcome. Journal of Clinical Oncology, 2006, 24, e16-e17.	1.6	35
179	Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. International Journal of Gynecological Cancer, 2008, 18, 363-368.	2.5	35
180	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35

#	Article	IF	CITATIONS
181	Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. European Journal of Cancer, 2016, 65, 185-191.	2.8	35
182	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. International Journal of Gynecological Cancer, 2019, 29, 676-682.	2.5	35
183	Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. Annals of Oncology, 2019, 30, 85-95.	1.2	35
184	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
185	Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecologic Oncology, 2003, 90, 372-377.	1.4	34
186	Long-Term Sexual Functioning in Women After Surgical Treatment of Cervical Cancer Stages IA to IB: A Prospective Controlled Study. International Journal of Gynecological Cancer, 2014, 24, 1527-1534.	2.5	34
187	Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma, 2015, 2015, 1-14.	1.3	34
188	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 415-422.	2.8	34
189	Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245.	3.8	34
190	Integration and validation of the ex vivo human placenta perfusion model. Journal of Pharmacological and Toxicological Methods, 2017, 88, 25-31.	0.7	34
191	Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced, Recurrent, or Metastatic Vulvar Cancer. International Journal of Gynecological Cancer, 2012, 22, 865-868.	2.5	33
192	Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies. Therapeutic Advances in Medical Oncology, 2013, 5, 211-219.	3.2	33
193	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacology & mp; Toxicology, 2015, 16, 2.	2.4	33
194	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Research and Treatment, 2018, 168, 551-557.	2.5	33
195	Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology. International Journal of Gynecological Cancer, 2012, 22, 407-416.	2.5	33
196	The management of borderline tumours of the ovary. Current Opinion in Oncology, 2006, 18, 488-493.	2.4	32
197	Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?. International Journal of Gynecological Cancer, 2006, 16, 273-277.	2.5	32
198	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	2.5	32

#	Article	IF	Citations
199	Psychologic, Relational, and Sexual Functioning in Women After Surgical Treatment of Vulvar Malignancy: A Prospective Controlled Study. International Journal of Gynecological Cancer, 2014, 24, 372-380.	2.5	32
200	Patient-Derived Xenograft Models for Endometrial Cancer Research. International Journal of Molecular Sciences, 2018, 19, 2431.	4.1	32
201	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. Frontiers in Nutrition, 2018, 5, 138.	3.7	32
202	Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB–IV epithelial ovarian cancer. Gynecologic Oncology, 2010, 116, 489-496.	1.4	31
203	Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners. Psycho-Oncology, 2017, 26, 1215-1221.	2.3	31
204	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma <i>In Situ</i> Cancer Research, 2019, 79, 1646-1657.	0.9	31
205	Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. European Journal of Cancer, 2020, 138, 57-67.	2.8	31
206	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	2.2	31
207	Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. International Journal of Gynecological Cancer, 2005, 15, 1210-1212.	2.5	30
208	Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?. Gynecologic Oncology, 2010, 119, 1-2.	1.4	30
209	Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1465-1468.	2.8	30
210	Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment. International Journal of Gynecological Cancer, 2014, 24, 468-477.	2.5	30
211	Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 845-857.	2.8	30
212	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€"an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30
213	Neoadjuvant Chemotherapy Followed by Surgery for Advanced-Stage Endometrial Cancer. Current Oncology, 2019, 26, 226-232.	2.2	30
214	AIF4-induced inhibition of the ATPase activity, the Ca2+-transport activity and the phosphoprotein-intermediate formation of plasma-membrane and endo(sarco)plasmic-reticulum Ca2+-transport ATPases in different tissues. Evidence for a tissue-dependent functional difference. Biochemical Journal, 1989, 261, 655-660.	3.7	29
215	A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. European Journal of Cancer, 2013, 49, 625-632.	2.8	29
216	Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. International Journal of Gynecological Cancer, 2006, 16, 183-188.	2.5	28

#	Article	IF	CITATIONS
217	Management and outcome of colorectal cancer during pregnancy: report of 41 cases. Acta Chirurgica Belgica, 2019, 119, 166-175.	0.4	28
218	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. Frontiers in Oncology, 2019, 9, 1073.	2.8	28
219	Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecologic Oncology, 2008, 111, 502-508.	1.4	27
220	Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?. Gynecologic Oncology, 2012, 124, 1-2.	1.4	27
221	Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. European Journal of Cancer, 2016, 61, 52-60.	2.8	27
222	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. JAMA Network Open, 2021, 4, e2113180.	5.9	27
223	Gynecologic oncology in pregnancy. Critical Reviews in Oncology/Hematology, 2008, 67, 187-195.	4.4	26
224	Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment, 2009, 114, 103-112.	2.5	26
225	Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Research and Treatment, 2011, 128, 429-435.	2.5	26
226	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecologic Oncology, 2015, 138, 165-173.	1.4	26
227	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer, 2017, 117, 840-847.	6.4	26
228	Imaging modalities in pregnant cancer patients. International Journal of Gynecological Cancer, 2021, 31, 423-431.	2.5	26
229	Hepatic necrosis and haemorrhage in pregnant patients with antiphospholipid antibodies. Lupus, 1997, 6, 552-555.	1.6	25
230	Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Annals of Oncology, 2011, 22, 588-594.	1.2	25
231	Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer. Journal of Clinical Oncology, 2013, 31, 3127-3132.	1.6	25
232	Myocardial function in children after fetal chemotherapy exposure. A tissue Doppler and myocardial deformation imaging study. European Journal of Pediatrics, 2013, 172, 163-170.	2.7	25
233	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	3.1	25
234	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Research and Treatment, 2016, 156, 319-330.	2.5	25

#	Article	lF	CITATIONS
235	Ageâ€dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Human Brain Mapping, 2019, 40, 4994-5010.	3.6	25
236	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	8.4	25
237	Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review. Cancers, 2021, 13, 1008.	3.7	25
238	Endometrial stromal sarcoma with a sole $t(X;17)$ chromosome change: report of a case and review of the literature. Gynecologic Oncology, 2003, 88, 459-462.	1.4	24
239	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2106-2109.	2.5	24
240	Wilms Tumor Gene 1(WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma. International Journal of Gynecological Cancer, 2011, 21, 302-308.	2.5	24
241	Polypoid endometriosis of the bladder during pregnancy mimicking urachal carcinoma. Ultrasound in Obstetrics and Gynecology, 2011, 38, 475-478.	1.7	24
242	Management of Gynecological Cancers During Pregnancy. Current Oncology Reports, 2014, 16, 415.	4.0	24
243	DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. British Journal of Cancer, 2015, 112, 1656-1664.	6.4	24
244	Fertility preserving management in gynecologic cancer patients: the need for centralization. International Journal of Gynecological Cancer, 2010, 20, 1613-9.	2.5	24
245	Predicting the clinical behavior of ovarian cancer from gene expression profiles. International Journal of Gynecological Cancer, 2006, 16, 147-151.	2.5	23
246	Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. Oncologist, 2008, 13, 410-414.	3.7	23
247	Cancer in pregnancy: safety and efficacy of systemic therapies. Current Opinion in Oncology, 2017, 29, 328-334.	2.4	23
248	Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. PLoS ONE, 2015, 10, e0124974.	2.5	23
249	Uterine Carcinosarcoma With Melanocytic Differentiation. International Journal of Gynecological Pathology, 2001, 20, 186-190.	1.4	22
250	INTRAVASCULAR LARGE B-CELL LYMPHOMA OF THE UTERUS PRESENTING AS FEVER OF UNKNOWN ORIGIN (FUO) AND REVEALED BY FDG-PET. Acta Clinica Belgica, 2007, 62, 187-190.	1.2	22
251	Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study. International Journal of Gynecological Cancer, 2011, 21, 316-322.	2.5	22
252	Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis, 2011, 32, 331-335.	2.8	22

#	Article	IF	Citations
253	Effects of Fetal Exposure to Maternal Chemotherapy. Paediatric Drugs, 2013, 15, 329-334.	3.1	22
254	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	2.5	22
255	Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. Sarcoma, 2015, 2015, 1-14.	1.3	22
256	Morcellation of uterine leiomyomas: a plea for patient triage. Lancet Oncology, The, 2015, 16, 1454-1456.	10.7	22
257	Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors. International Journal of Gynecological Cancer, 2016, 26, 1399-1406.	2.5	22
258	Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case Reports in Oncology, 2018, 11, 119-124.	0.7	22
259	Transplacental transport of paracetamol and its phase II metabolites using the ex vivo placenta perfusion model. Toxicology and Applied Pharmacology, 2019, 370, 14-23.	2.8	22
260	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. European Journal of Surgical Oncology, 2019, 45, 67-74.	1.0	22
261	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	2.0	22
262	Pseudomyxoma Peritonei Associated With a Mucinous Ovarian Tumor Arising From a Mature Cystic Teratoma. A Case Report. International Journal of Gynecological Pathology, 2006, 25, 340-343.	1.4	21
263	Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 1147-1151.	2.5	21
264	The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study. International Journal of Gynecological Cancer, 2011, 21, 332-336.	2.5	21
265	Growth Differentiation Factor-15 as Biomarker in Uterine Sarcomas. International Journal of Gynecological Cancer, 2014, 24, 252-259.	2.5	21
266	Genetic and microscopic assessment of the human chemotherapy-exposed placenta reveals possible pathways contributive to fetal growth restriction. Placenta, 2018, 64, 61-70.	1.5	21
267	Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1811-1823.	2.5	21
268	The MNK1/2–elF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. Cancer Research, 2021, 81, 3876-3889.	0.9	21
269	Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. International Journal of Gynecological Cancer, 2019, 29, 404-416.	2.5	21
270	Second case of uterine mesonephric adenocarcinoma. International Journal of Gynecological Cancer, 2006, 16, 1450-1454.	2.5	20

#	Article	IF	Citations
271	Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Gynecologic Oncology, 2006, 102, 415-417.	1.4	20
272	Should we screen for endometrial cancer?. Lancet Oncology, The, 2011, 12, 4-5.	10.7	20
273	Cancer during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 443-446.	2.8	20
274	Nonâ€invasive prenatal testing suggesting a maternal malignancy: What do we tell the prospective parents in Belgium?. Prenatal Diagnosis, 2021, 41, 1264-1272.	2.3	20
275	Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature. International Journal of Gynecological Cancer, 2009, 19, 245-248.	2.5	20
276	Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Research, 2010, 30, 3709-14.	1.1	20
277	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment, 2007, 106, 127-133.	2.5	19
278	Vinblastine and doxorubicin administration to pregnant mice affects brain development and behaviour in the offspring. NeuroToxicology, 2009, 30, 647-657.	3.0	19
279	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecologic Oncology, 2015, 138, 278-284.	1.4	19
280	Noninvasive Prenatal Testing and Detection of Occult Maternal Malignancies. Clinical Chemistry, 2019, 65, 1484-1486.	3.2	19
281	Influence of the corticospinal tract wiring pattern on sensorimotor functional connectivity and clinical correlates of upper limb function in unilateral cerebral palsy. Scientific Reports, 2019, 9, 8230.	3.3	19
282	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment, 2009, 115, 349-358.	2.5	18
283	Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. European Journal of Cancer, 2012, 48, 1332-1340.	2.8	18
284	Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. British Journal of Radiology, 2016, 89, 20160468.	2.2	18
285	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 79-88.	2.8	18
286	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
287	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 2019, 30, e86.	2.2	18
288	Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. Anticancer Research, 2011, 31, 2367-71.	1.1	18

#	Article	IF	Citations
289	Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 82, 46-59.	2.8	18
290	Lymphadenectomy in endometrial cancer. Lancet, The, 2009, 373, 1169-1170.	13.7	17
291	Conditioning of the abdominal cavity reduces tumor implantation in a laparoscopic mouse model. Surgery Today, 2014, 44, 1328-1335.	1.5	17
292	Sentinel-lymph-node mapping in endometrial cancer: routine practice?. Lancet Oncology, The, 2017, 18, 281-282.	10.7	17
293	Maternal and obstetrical outcome in 35 cases of wellâ€differentiated thyroid carcinoma during pregnancy. Laryngoscope, 2018, 128, 1493-1500.	2.0	17
294	Pregnant women with confirmed neoplasms should not have noninvasive prenatal testing. Prenatal Diagnosis, 2019, 39, 1162-1165.	2.3	17
295	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. Scientific Reports, 2021, 11, 3176.	3.3	17
296	Wnt \hat{l}^2 -Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 705384.	2.8	17
297	To the Editor. Gynecologic Oncology, 2002, 84, 537.	1.4	16
298	Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?. Breast Cancer Research and Treatment, 2008, 107, 79-86.	2.5	16
299	Genetic changes in nonepithelial ovarian cancer. Expert Review of Anticancer Therapy, 2013, 13, 871-882.	2.4	16
300	Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. Melanoma Research, 2017, 27, 218-223.	1.2	16
301	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. Gynecologic Oncology, 2017, 146, 538-545.	1.4	16
302	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. Journal of the Society for Gynecologic Investigation, 2003, 10, 105-109.	1.7	16
303	The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecologic Oncology, 2005, 99, 521-522.	1.4	15
304	Primary Retroperitoneal Mucinous Cystadenocarcinoma: A Case Report and Review of the Literature. Gynecologic and Obstetric Investigation, 2010, 70, 186-191.	1.6	15
305	EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2012, 22, 875-880.	2.5	15
306	Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenatal Diagnosis, 2012, 32, 614-619.	2.3	15

#	Article	IF	CITATIONS
307	Evaluation of the quality of the management of cancer of the corpus uteri â€" Selection of relevant quality indicators and implementation in Belgium. Gynecologic Oncology, 2013, 131, 512-519.	1.4	15
308	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Breast, 2014, 23, 453-459.	2.2	15
309	Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues?. BMC Cancer, 2018, 18, 192.	2.6	15
310	Lymphoblastic lymphoma presenting as bilateral gigantomastia in pregnancy. International Journal of Gynecology and Obstetrics, 2005, 91, 252-253.	2.3	14
311	Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. International Journal of Gynecological Cancer, 2007, 17, 83-87.	2.5	14
312	Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Research and Treatment, 2009, 118, 531-538.	2.5	14
313	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. Journal of Translational Medicine, 2014, 12, 179.	4.4	14
314	Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I–II Cervical Cancer. International Journal of Gynecological Cancer, 2017, 27, 1256-1260.	2.5	14
315	Maternal and neonatal outcomes in 80 patients diagnosed with nonâ∈Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. British Journal of Haematology, 2021, 193, 52-62.	2.5	14
316	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. Cancers, 2021, 13, 3988.	3.7	14
317	Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions. Cancers, 2022, 14, 1966.	3.7	14
318	Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer, 2008, 8, 18.	2.6	13
319	Application of proteomics in ovarian cancer: Which sample should be used?. Gynecologic Oncology, 2009, 115, 497-503.	1.4	13
320	The Use of Lymph Vessel Markers to Predict Endometrial Cancer Outcome. International Journal of Gynecological Cancer, 2010, 20, 363-367.	2.5	13
321	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. European Journal of Cancer, 2022, 170, 54-63.	2.8	13
322	Cumulative dosage effect of aRAD51l1/HMGA2 fusion and RAD51l1 loss in a case of pseudo-Meigs' syndrome. Genes Chromosomes and Cancer, 2001, 32, 324-329.	2.8	12
323	Immunohistochemical determination of hormone receptors in uterine adenosarcomas. Gynecologic Oncology, 2003, 88, 463-464.	1.4	12
324	2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecologic Oncology, 2003, 91, 299-308.	1.4	12

#	Article	IF	CITATIONS
325	A possible role of the cytochrome P450c17α gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 234-239.	2.8	12
326	Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB. Journal of Clinical Oncology, 2008, 26, 5654-5655.	1.6	12
327	Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma. International Journal of Gynecological Cancer, 2012, 22, 617-622.	2.5	12
328	Tongue cancers during pregnancy: Case reports and review of literature. Head and Neck, 2013, 35, E102-8.	2.0	12
329	Development of Patient-Derived Tumor Xenograft Models. Methods in Molecular Biology, 2019, 1862, 217-225.	0.9	12
330	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
331	Abstract S6-2: 313 Patients with Breast Cancer during Pregnancy — Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03). , 2010, , .		12
332	Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series. Clinical Pharmacology and Therapeutics, 2022, 112, 404-410.	4.7	12
333	Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. Gynecologic Oncology, 2005, 98, 523-524.	1.4	11
334	CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecologic Oncology, 2005, 99, 493-496.	1.4	11
335	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Breast Cancer Research and Treatment, 2008, 110, 153-159.	2.5	11
336	Successful conservative treatment of endocervical adenocarcinoma stage lb1 diagnosed early in pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 250-253.	2.8	11
337	Screening for ovarian carcinoma: not quite there yet. Lancet Oncology, The, 2009, 10, 308-309.	10.7	11
338	LATE RECURRENT OVARIAN CARCINOMA METASTATIC TO THE THORACIC WALL. Acta Clinica Belgica, 2010, 65, 354-356.	1.2	11
339	Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: An analysis of 163 patients. European Journal of Cancer, 2011, 47, 191-198.	2.8	11
340	Being Pregnant and Diagnosed with Breast Cancer. Breast Care, 2012, 7, 204-209.	1.4	11
341	Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncology Reports, 2013, 29, 413-418.	2.6	11
342	Contraception is as important as fertility preservation in young women with cancer. Lancet, The, 2015, 385, 508.	13.7	11

#	Article	IF	Citations
343	Long-term prognosis of young breast cancer patients (â‰#0 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	1.9	11
344	Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. Cancers, 2021, 13, 1214.	3.7	11
345	Role of Diaphragmatic Surgery in 69 Patients With Ovarian Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 481-481.	2.5	11
346	Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer. Gynecologic and Obstetric Investigation, 2009, 67, 46-48.	1.6	10
347	Expression of ERCC1, p53, and Class III \hat{I}^2 -Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer. International Journal of Gynecological Cancer, 2011, 21, 1071-1077.	2.5	10
348	Fetal Rat Hearts Do Not Display Acute Cardiotoxicity in Response to Maternal Doxorubicin Treatment. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 362-369.	2.5	10
349	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. Endoscopy, 2016, 48, 1016-1022.	1.8	10
350	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. New England Journal of Medicine, 2016, 374, 692-693.	27.0	10
351	Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer. Gynecologic and Obstetric Investigation, 2018, 83, 620-626.	1.6	10
352	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10
353	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. Cancers, 2020, 12, 3623.	3.7	10
354	Incorporating molecular profiling into endometrial cancer management requires prospective studies. International Journal of Gynecological Cancer, 2021, 31, 944-945.	2.5	10
355	Complete hydatidiform mole with co-existing healthy fetus: A case report. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 341-344.	1.5	9
356	Is It Safe to Treat Endometrial Carcinoma Endoscopically?. Journal of Clinical Oncology, 2009, 27, 5305-5307.	1.6	9
357	The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy. International Journal of Gynecological Cancer, 2010, 20, 542-551.	2.5	9
358	The "Leuven―paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. Gynecologic Oncology, 2013, 128, 34-37.	1.4	9
359	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. Lancet Oncology, The, 2016, 17, 273-274.	10.7	9
360	Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 61-67.	2.5	9

#	Article	IF	CITATIONS
361	Asparaginaseâ€like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1695-1703.	2.3	9
362	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. Acta Clinica Belgica, 2020, 75, 9-18.	1.2	9
363	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. Frontiers in Oncology, 2020, 10, 538064.	2.8	9
364	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. Clinical Chemistry, 2020, 66, 1414-1423.	3.2	9
365	Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2021, 222, 113562.	5.5	9
366	Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology. International Journal of Gynecological Cancer, $2011, 21, 1$.	2.5	9
367	TRP channel expression correlates with the epithelial–mesenchymal transition and high-risk endometrial carcinoma. Cellular and Molecular Life Sciences, 2022, 79, 1.	5.4	9
368	Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristone. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 120, 233-235.	1.1	8
369	The Addition of 4% Oxygen to the CO2 Pneumoperitoneum Does Not Decrease Dramatically Port Site Metastases. Journal of Minimally Invasive Gynecology, 2008, 15, 700-703.	0.6	8
370	Feasibility of Ultrasound-guided Percutaneous Samplings in the Pregnant Baboon: A Model for Studies on Transplacental Transport. Reproductive Sciences, 2009, 16, 280-285.	2.5	8
371	Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot study. Fertility and Sterility, 2009, 91, 1441-1444.	1.0	8
372	High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. Journal of Medical Case Reports, 2010, 4, 243.	0.8	8
373	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. Cancer Chemotherapy and Pharmacology, 2011, 68, 1347-1353.	2.3	8
374	Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate–etoposide. Gynecologic Oncology, 2012, 127, 47-50.	1.4	8
375	In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer. Journal of Immunotherapy, 2015, 38, 239-249.	2.4	8
376	Characteristics and prognosis of patients with early-stage endometrial cancer who refuse adjuvant radiotherapy. Gynecologic Oncology, 2016, 141, 428-433.	1.4	8
377	Effects of in-utero exposure to chemotherapy on fetal brain growth. International Journal of Gynecological Cancer, 2019, 29, 1195-1202.	2.5	8
378	The misoprostal third stage study: a randomsed controlled comparison between orally administreted misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 338-338.	2.3	7

#	Article	IF	CITATIONS
379	PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas. American Journal of Obstetrics and Gynecology, 2002, 187, 258.	1.3	7
380	Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study. International Journal of Gynecological Cancer, 2009, 19, 1505-1510.	2.5	7
381	Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?. International Journal of Gynecological Cancer, 2009, 19, 1501-1504.	2.5	7
382	Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking. Expert Opinion on Drug Safety, 2014, 13, 1653-1665.	2.4	7
383	Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLoS ONE, 2017, 12, e0182223.	2.5	7
384	A Real-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients. Gynecologic and Obstetric Investigation, 2018, 83, 156-163.	1.6	7
385	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. Vaccines, 2018, 6, 56.	4.4	7
386	Executive functioning in 6Âyear old children exposed to chemotherapy in utero. Early Human Development, 2020, 151, 105198.	1.8	7
387	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	2.8	7
388	Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands. European Journal of Cancer, 2022, 171, 13-21.	2.8	7
389	Progesterone Receptor in Estrogen Receptor–Positive Breast Cancer: The Association Between HER-2 and Lymph Node Involvement Is Age Related. Journal of Clinical Oncology, 2006, 24, 2595-2595.	1.6	6
390	Laparoscopic hysterectomy for early endometrial cancer. Lancet Oncology, The, 2010, 11, 707-708.	10.7	6
391	<i>Kit</i> Gene in Endometrial Carcinoma: An Immunohistochemical and Mutational Analysis. International Journal of Gynecological Cancer, 2011, 21, 203-205.	2.5	6
392	ESGO Statement on the Role of CAâ€125 Measurement in Follow-Up of Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 175-175.	2.5	6
393	Is chemotherapy during the first trimester of pregnancy really safe?. International Journal of Cancer, 2013, 132, 1728-1728.	5.1	6
394	Dendritic cell immunotherapy in uterine cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 1822-1827.	3.3	6
395	Microsatellite Instable and Microsatellite Stable Primary Endometrial Carcinoma Cells and Their Subcutaneous and Orthotopic Xenografts Recapitulate the Characteristics of the Corresponding Primary Tumor. International Journal of Gynecological Cancer, 2015, 25, 363-371.	2.5	6
396	Effects of prenatal exposure to cancer treatment on neurocognitive development, a review. NeuroToxicology, 2016, 54, 11-21.	3.0	6

#	Article	IF	Citations
397	Placental pathology in cancer during pregnancy and after cancer treatment exposure. Placenta, 2021, 111, 33-46.	1.5	6
398	Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. Anticancer Research, 2016, 36, 5381-5384.	1.1	6
399	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	3.2	6
400	Bifunctional pathway of uterine carcinosarcomas. Human Pathology, 2003, 34, 299.	2.0	5
401	Urachal carcinoma during pregnancy. Urology, 2006, 67, 1290.e19-1290.e21.	1.0	5
402	Aromatase Inhibitors in Premenopausal Women: The Need for Proper Contraceptive Counseling. Breast Journal, 2006, 12, 507-508.	1.0	5
403	Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients. International Journal of Gynecological Cancer, 2006, 16, 1885-1893.	2.5	5
404	Fertility Preservation in (Breast) Cancer Patients: Is it Safe?. Journal of Clinical Oncology, 2006, 24, 5335-5336.	1.6	5
405	Sonographic biometrical normograms and estimation of fetal weight in the baboon (<i>Papio) Tj ETQq1 1 0.7843</i>	314 rgBT /	Overlock 10
406	The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. Gynecologic Oncology, 2010, 118, 64-68.	1.4	5
407	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis, 2011, 32, 1862-1866.	2.8	5
408	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. Gynecologic Oncology, 2015, 138, 378-382.	1.4	5
409	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1	0,78431	4 rgBT /Over
410	Mesonephric (Wolffian) Pseudoendometrioid Carcinoma of the Broad Ligament, Arising From a Papillary Cystadenoma. International Journal of Surgical Pathology, 2016, 24, 635-639.	0.8	5
411	Comment on "Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review― European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 216, 261-262.	1.1	5
412	Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors. Gynecologic and Obstetric Investigation, 2018, 83, 65-69.	1.6	5
413	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology, 2019, 89, 90-98.	2.0	5
414	Chemotherapy During Pregnancy: Careful Fetal Growth Monitoring Is Mandatory. JCO Oncology Practice, 2020, 16, 559-560.	2.9	5

#	Article	IF	CITATIONS
415	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	2.5	5
416	Liver involvement in HELLP syndrome: CT and MRI findings in two patients. European Radiology, 1995, 5, 331-334.	4.5	4
417	Gastrostomy Using a "Gastrofix―as an Alternative for Nasogastric Tubes in Ovarian Cancer Surgery. Gynecologic Oncology, 1998, 71, 348-351.	1.4	4
418	The misoprostal third stage study: a randomsed controlled comparison between orally administreted misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. British Journal of Obstetrics and Gynaecology, 2001, 108, 338.	0.9	4
419	Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma. Gynecologic Oncology, 2004, 93, 272-273.	1.4	4
420	Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor. Breast Care, 2008, 3, 8-8.	1.4	4
421	In Early-Stage Breast Cancer, the Estrogen Receptor Interacts With Correlation Between Human Epidermal Growth Factor Receptor 2 Status and Age at Diagnosis, Tumor Grade, and Lymph Node Involvement. Journal of Clinical Oncology, 2008, 26, 1768-1769.	1.6	4
422	Reproduction Rates After Cytotoxic Therapy. Journal of Clinical Oncology, 2009, 27, e118-e119.	1.6	4
423	Use of general anesthesia and sentinel node procedure during pregnancy. Journal of Surgical Oncology, 2012, 106, 1008-1008.	1.7	4
424	External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. Gynecologic Oncology, 2016, 142, 83-88.	1.4	4
425	Data describing child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. Data in Brief, 2020, 32, 106209.	1.0	4
426	Renal and Bladder Cancer During Pregnancy: A Review of 47 Cases and Literature-based Recommendations for Management. Urology, 2021, 151, 118-128.	1.0	4
427	Cervical cancer in pregnancy at various gestational ages. International Journal of Gynecological Cancer, 2021, 31, 784-788.	2.5	4
428	Long-term neurodevelopmental outcome after prenatal exposure to maternal hematological malignancies with or without cytotoxic treatment. Child Neuropsychology, 2021, 27, 822-833.	1.3	4
429	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers, 2021, 13, 2040.	3.7	4
430	Fertility sparing treatment in cervical cancer management in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 75, 101-112.	2.8	4
431	Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP) Journal of Clinical Oncology, 2014, 32, 1071-1071.	1.6	4
432	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial Journal of Clinical Oncology, 2017, 35, TPS5613-TPS5613.	1.6	4

#	Article	IF	CITATIONS
433	Proton therapy of a pregnant patient with nasopharyngeal carcinoma. Clinical and Translational Radiation Oncology, 2022, 35, 33-36.	1.7	4
434	Improving outcome in the first-line management of advanced ovarian cancer. European Journal of Cancer, Supplement, 2007, 5, 23-28.	2.2	3
435	Wilms' tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours. Histopathology, 2009, 54, 384-387.	2.9	3
436	Psycho-Oncology: Structure and Profiles of European Centers Treating Patients With Gynecological Cancer. International Journal of Gynecological Cancer, 2011, 21, 1520-1524.	2.5	3
437	FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA. Histopathology, 2014, 65, 371-388.	2.9	3
438	Reply to D. Crivellari et al. Journal of Clinical Oncology, 2014, 32, 255-256.	1.6	3
439	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. International Journal of Molecular Sciences, 2016, 17, 1525.	4.1	3
440	Long-term impact of prenatal exposure to chemotherapy on executive functioning: An ERP study. Clinical Neurophysiology, 2019, 130, 1655-1664.	1.5	3
441	Novel next-generation sequencing-based methodologies to characterize the mutational consequences of (prenatal) chemotherapy exposure in noncancerous tissue. Current Opinion in Oncology, 2021, 33, 476-484.	2.4	3
442	The progesterone receptor has a prognostic value in oestrogen receptor negative breast cancers. European Journal of Cancer, Supplement, 2004, 2, 103-104.	2.2	2
443	Role of cyclin-dependent kinase p27 in uterine carcinosarcomas. International Journal of Gynecological Cancer, 2005, 15, 986-987.	2.5	2
444	Residual tumor after neoadjuvant chemotherapy and interval debulking surgery for advanced endometrial cancer. Gynecologic Oncology, 2009, 114, 370.	1.4	2
445	What is the role of neoadjuvant chemotherapy in advanced endometrial cancer?. Gynecologic Oncology, 2010, 119, 601.	1.4	2
446	Reply to H.A. Azim Jr et al. Journal of Clinical Oncology, 2010, 28, e304-e304.	1.6	2
447	Cognitive and Cardiac Outcome After Prenatal Exposure to Chemotherapy in Children 18 Months or Older. European Journal of Cancer, 2011, 47, 8.	2.8	2
448	Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. Menopause, 2011, 18, 224-229.	2.0	2
449	Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed childrenÂwith nonexposed controls. American Journal of Obstetrics and Gynecology, 2015, 212, 830-831.	1.3	2
450	Endometrial cancer during pregnancy: management strategies. International Journal of Gynecological Cancer, 2019, 29, 1221-1224.	2.5	2

#	Article	IF	CITATIONS
451	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	1.0	2
452	Association of a novel set of 7 homopolymer indels for detection of MSI with tumor mutation burden and total indel load in endometrial and colorectal cancers Journal of Clinical Oncology, 2018, 36, e15654-e15654.	1.6	2
453	Implementation of cancer treatment during pregnancy in daily practice: the important role of perinatologists. Oncotarget, 2018, 9, 31795-31796.	1.8	2
454	Letter to the Editor. Gynecologic Oncology, 2004, 94, 607.	1.4	1
455	Laparoscopy and peritoneal tuberculosis. International Journal of Gynecology and Obstetrics, 2006, 95, 58-59.	2.3	1
456	Molecular profiling of platinum resistant ovarian cancer: Use of the model in clinical practice. International Journal of Cancer, 2006, 119, 1511-1511.	5.1	1
457	Use of chemotherapy during pregnancy in the treatment of ovarian malignancies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 156, 237.	1.1	1
458	Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting., 2011,, 209-227.		1
459	796 Establishment of Primary Endometrial Carcinoma Cell Cultures as a Preclinical Tool for Drug Screening – Methods and Characterization. European Journal of Cancer, 2012, 48, S189-S190.	2.8	1
460	Trastuzumab, lapatinib and bevacizumab during pregnancy. Breast Cancer Management, 2013, 2, 5-7.	0.2	1
461	Optimal Staging of Lymphoma during Pregnancy is Crucial. Women's Health, 2015, 11, 101-102.	1.5	1
462	Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials, 2013,,.		1
463	Atypical Lesions of the Breast and Lobular Carcinoma in Situ in Pregnancy – Surgeons' Practice. The Journal of Breast Health, 2020, 16, 16-21.	1.0	1
464	P2-17-09: A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen , 2011, , .		1
465	Neonatal and Long-Term Consequences of In Utero Exposure to Systemic Anticancer Therapy. , 2016, , 97-110.		1
466	Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4. International Journal of Gynecological Cancer, 2019, 29, 1304-1310.	2.5	1
467	Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT). BMC Cancer, 2022, 22, .	2.6	1
468	Low-grade serous ovarian cancer in pregnancy. International Journal of Gynecological Cancer, 2022, 32, 804-808.	2.5	1

#	Article	IF	CITATIONS
469	Women under age 50 with an ER-positive breast cancer are more likely to have positive lymph nodes if PR is not expressed. European Journal of Cancer, Supplement, 2004, 2, 179.	2.2	O
470	Role of adnexectomy in the surgical treatment of cervical adenocarcinoma. International Journal of Gynecological Cancer, 2005, 15, 984.	2.5	0
471	Different Subtypes of Uterine Sarcoma Require a Separate Therapeutic Approach. Women's Health, 2005, 1, 375-383.	1.5	O
472	Methodology in plasma proteomic pattern experiments. International Journal of Gynecological Cancer, 2006, 16, 1951-1952.	2.5	0
473	Dormant foci of endometrial stromal sarcoma as an intermediate between an indolent and aggressive growth. Gynecologic Oncology, 2007, 105, 278-279.	1.4	0
474	P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive. Breast, 2007, 16, S27.	2.2	0
475	0090 Axillary staging of breast cancer with the sentinel lymph node (SLN) procedure in over a thousand patients with early breast cancer. Breast, 2009, 18, S41.	2.2	0
476	0139 Why 28% of ER-negative/PR-negative breast cancer (BC) patients did not get chemotherapy (CT). Breast, 2009, 18, S53.	2.2	0
477	0192 Does the stellate ganglion block reduce severe hot flushes and sleep disturbances in breast cancer patients?. Breast, 2009, 18, S67.	2.2	0
478	Revised FIGO staging for endometrial cancer. Southern African Journal of Gynaecological Oncology, 2010, 2, 40-41.	0.3	0
479	298 INVITED Management Aimed at Fertility Preservation. European Journal of Cancer, 2011, 47, S68.	2.8	0
480	Gynecological Cancer During Pregnancy. , 2011, , 77-96.		0
481	1090 Tumor-associated Antigen Validation in Uterine Tumors. European Journal of Cancer, 2012, 48, S262.	2.8	0
482	IN23 Breast cancer during pregnancy: the obstetrician/paediatric perspective. Breast, 2012, 21, S8.	2.2	0
483	15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft models. European Journal of Cancer, 2014, 50, 11.	2.8	0
484	Breastfeeding a child on treatment for childhood cancer. Journal of Oncology Pharmacy Practice, 2014, 20, 237-238.	0.9	0
485	705 Whole-body diffusion-weighted MRI for staging of women with cancer during pregnancy: A pilot study. European Journal of Cancer, 2015, 51, S129.	2.8	0
486	3205 Obstetrical complications and neonatal outcome in patients diagnosed with acute myeloid and acute lymphoblastic leukemia during pregnancy: Results from the International Network on Cancer, Infertility and Pregnancy (INCIP) study. European Journal of Cancer, 2015, 51, S650.	2.8	0

#	Article	IF	CITATIONS
487	Morcellation of presumed benign uterine tumors: abandon the technique or patient triage?. Gynecological Surgery, 2015, 12, 1-2.	0.9	O
488	Low-grade bronchial mucoepidermoid carcinoma during pregnancy successfully treated by lobectomy. Journal of Obstetrics and Gynaecology, 2017, 37, 1082-1084.	0.9	0
489	Breast Cancer (Diagnosed) During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients., 2017,, 709-718.		0
490	Your contribution to Gynecological Surgery now freely available to the global scientific community. Gynecological Surgery, 2017, 14 , .	0.9	0
491	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. Reproductive Sciences, 2018, 25, 1637-1648.	2.5	0
492	AUTHOR REPLY. Urology, 2021, 151, 127-128.	1.0	0
493	Is weight of breast associated with hormone receptor expression in postmenopausal invasive breast cancer?. European Journal of Cancer, 2002, 38, S112.	2.8	0
494	Abstract P4-08-09: The Prognostic Importance of "Detection Mode―and "Palpability―in Primary Operable Grade 2 Breast Cancers. , 2010, , .		0
495	P4-09-07: Breast Cancer Outcome by Combined Immunohistochemical ER/PR/HER2 Receptor Phenotype, 2011,,.		0
496	P1-08-20: Parity Interferes with the Effect of Age at Diagnosis on the Frequency Breast Cancers Are Triple-Negative, 2011, , .		0
497	Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. , 2012, , .		0
498	Abstract P6-05-05: Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis., 2012,,.		0
499	Abstract P6-07-29: Independent prognostic value of age depends on breast cancer subtype. , 2012, , .		0
500	Abstract P2-10-12: How well predict the 2011 St Gallen early breast cancer surrogate phenotypes metastatic survival?., 2012,,.		0
501	Abstract P1-13-08: Arthralgia and changes in serum levels of IGF-I, its binding protein and estrogen in breast cancer patients on endocrine agents. , 2013, , .		0
502	Abstract PD2-3: High body mass index (BMI) and worse response to neoadjuvant chemotherapy (NACT) by breast cancer phenotype: Own data and external validation on German breast group (GBG) patients., 2013,,.		0
503	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms Journal of Clinical Oncology, 2014, 32, TPS5621-TPS5621.	1.6	0
504	Non-Invasive Detection of Genomic Imbalances in Hodgkin/Reed-Sternberg Cells in Early and Advanced Stage Hodgkin Lymphoma By Sequencing of Circulating Cell-Free DNA. Blood, 2014, 124, LBA-4-LBA-4.	1.4	0

#	ARTICLE	IF	CITATIONS
505	Abstract P6-09-12: Breast cancer characteristics and the levonorgestrel intrauterine device. A monocentric retrospective study. , 2016, , .		O
506	Abstract P6-10-06: The impact of body mass index on age at breast cancer diagnosis and breast cancer phenotype. , $2016, , .$		0
507	Surgical Principles of Endometrial Cancer. , 2020, , 153-174.		O
508	Management of Rare Uterine Malignant Tumors. , 2020, , 277-312.		0
509	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. Blood, 2021, 138, 2457-2457.	1.4	O
510	Gynaecological Cancers and Pregnancy. , 2021, , 602-611.		0